CapMan Press Release – 12 December 2012 at 3:00 pm EET
CapMan Real Estate and Tristan acquire an office building in the Greater Stockholm area in a sale and leaseback transaction for SEK 166 million
A joint venture between CapMan and CCP III, a fund advised by Tristan Capital Partners, has acquired Pfizer AB’s Swedish headquarters through a sale and leaseback transaction for SEK 166 million. The Malten 1 building is located in Sollentuna in the Greater Stockholm area.
The 16,000 square-metre office building was built in 2005 for Pfizer by Skanska and is positioned alongside the E4 motorway in Silverdal, in the municipality of Sollentuna, which is strategically located between Stockholm’s central business district and Arlanda Airport. BMW and Pfizer lease space in the building and there is a further 3,000 sqm of office space available for leasing. CapMan Real Estate will manage the property on behalf of the joint venture.
“We are excited about our partnership with CCP III and Tristan Capital Partners and the acquisition of this property. We very much look forward to working with the existing tenants, Pfizer and BMW, and also to introducing new tenants to the high quality space available within the building,” says Ed Williams of CapMan Real Estate.
“This acquisition represents an opportunity for our Curzon Capital Partners III core plus fund to acquire a high quality property with vacancy and to take advantage of a strong economy and leasing market where an active asset management strategy can add value through the presence on the ground of our local partner CapMan,” says Cameron Spry, Head of Investments at Tristan Capital Partners.
“This acquisition is the first one closed in Sweden since we established CapMan Real Estate’s operations in Stockholm a year ago. It is perfectly in line with our value-add investment strategy we have executed also in our past real estate funds,” comments Mika Matikainen, Head of CapMan Real Estate.
CapMan Real Estate manages four real estate funds: the CapMan Real Estate I fund, which invests in commercial properties in Greater Helsinki, the CapMan RE II fund, which invests in commercial and development projects around Finland, the CapMan Hotels RE fund, which invests in hotel properties, primarily in Finland and CapMan’s first project-specific hotel property fund, CapMan Yrjönkatu 17 Ky, which owns a hotel in central Helsinki.
For further information, please contact:
Mika Matikainen, Senior Partner, Head of CapMan Real Estate, tel. +358 (0)20 720 7616
Ed Williams, CapMan Real Estate, tel. +46 (0)8 445 1051
Monica O’Neill, Tristan Capital Partners, tel. +44 (0)20 3463 8868, email: email@example.com
Christina Astrén Eriksson, Head Communication, Pfizer AB, tel. + 46 (0)8 550 52958
CapMan is one of the leading private equity firms in the Nordic countries and Russia, with assets under management of 3.0 billion. CapMan has four key investment partnerships – CapMan Buyout, CapMan Russia, CapMan Public Market, and CapMan Real Estate – each of which has its own dedicated investment team and funds. Altogether, CapMan employs approx. 110 people in Helsinki, Stockholm, Oslo, Moscow and Luxembourg. CapMan was established in 1989 and has been listed on the Helsinki Stock Exchange since 2001.
Tristan Capital Partners www.tristancap.com
Tristan Capital Partners is an employee owned boutique with extensive, multi-cycle European market experience specialising in public and private market real estate investment strategies of all property types across the UK and Continental Europe. Tristan is the Portfolio Manager for Curzon Capital Partners III and for the private equity funds European Property Investors, LP and European Property Investors Special Opportunities, LP, and together with core-plus strategy funds has over 3 billion in assets under management. Tristan’s headquarters is in London and has offices in Luxembourg, Milan, Paris, Stockholm, Dusseldorf and Warsaw.
Pfizer Inc.: Working together for a healthier world
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.